CSIMarket Company Name, Ticker, Industry, else..
 
Barinthus Biotherapeutics Plc  (NASDAQ: BRNS)
Other Ticker:  
 
 
Price: $0.9475 $0.01 0.798%
Day's High: $1.12 Week Perf: -17.61 %
Day's Low: $ 0.91 30 Day Perf: 0.8 %
Volume (M): 23 52 Wk High: $ 4.16
Volume (M$): $ 22 52 Wk Avg: $1.60
Open: $0.95 52 Wk Low: $0.80



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) -67
 Capital Exp. (TTM) (Millions $) 1

Barinthus Biotherapeutics Plc


   Company Address: Unit 6-10, Zeus Building Harwell, Didcot 0
   Company Phone Number: 1865 818 808   Stock Exchange / Ticker: NASDAQ BRNS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INO   -10.53%    
• View Complete Report
   



Management Changes

Barinthus Bios New CSO, Geoffrey Lynn, Faces Uphill Battle: Can Breakthroughs in Hepatitis B Resuscitate a Biotech Struggling with Losses,

Published Mon, Nov 25 2024 9:01 PM UTC

Barinthus Biotherapeutics Promotes Lynn Amid Financial Struggles: A Potential Rebirth in Hepatitis B Treatment?An Look into Barinthus Biotherapeutics and the Future of Hepatitis B TreatmentIn a surprising turn of events, Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company headquartered in Oxford, UK, has recently announced the promotion of Geoffrey Lyn...
Clinical Study

Breaking Boundaries in Hepatitis B Barinthus Bios Vanguard Victory in Phase 2b Trials,

Published Fri, Nov 15 2024 4:02 PM UTC

Breakthroughs in Chronic Hepatitis B Treatment: Barinthus Bio s Promising Phase 2b Trial Results AbstractChronic Hepatitis B (CHB) continues to be a major global health challenge, with millions affected worldwide. New therapeutic approaches are urgently needed to combat the disease and Barinthus Bio is at the forefront with promising results from its ongoing clinical trials...
Clinical Study

Barinthus Bio Breaks New Ground in Hepatitis B and Prostate Cancer Trials A Potential Paradigm Shift in Biotherapeutics

Published Tue, Oct 1 2024 12:00 PM UTC

In recent developments, Barinthus Biotherapeutics plc (NASDAQ: BRNS), a pioneering clinical-stage biopharmaceutical firm, has made significant strides in its clinical programs targeting chronic hepatitis B (CHB) and prostate cancer. Notably, the completion of enrollment for two critical clinical trials the Phase 2b HBV003 trial for chronic hepatitis B and the Phase 1 PCA001...
Clinical Study

Barinthus Bios Breakthrough Hepatitis B Immunotherapy Shines at EASL Congress 2024

Published Wed, Jun 12 2024 8:01 PM UTC

Barinthus Bio Prioritizes Strategic Pipeline and Presents Positive Data for Hepatitis B Immunotherapeutic Candidate at EASL Congress 2024OXFORD, United Kingdom, May 22, 2024 - Barinthus Biotherapeutics plc (NASDAQ: BRNS), a leading biopharmaceutical company focused on developing innovative T cell immunotherapeutic candidates to combat chronic infectious diseases, autoimmunit...
Clinical Study

Barinthus Bios VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance ...

Published Thu, Jun 6 2024 3:15 PM UTC

Breakthrough in Chronic Hepatitis B Treatment: Barinthus Bio s VTP-300 Trial Results Show PromiseIn a significant leap forward in the treatment of chronic hepatitis B, Barinthus Bio s VTP-300 has demonstrated remarkable efficacy in recent clinical trials. With updated data presented at the EASL Congress 2024, the biotechnology company highlights its potential game-changing ...






Barinthus Biotherapeutics Plc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com